BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 33521321)

  • 1. Targeting the JAK/STAT pathway in solid tumors.
    Qureshy Z; Johnson DE; Grandis JR
    J Cancer Metastasis Treat; 2020; 6():. PubMed ID: 33521321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
    Karati D; Mahadik KR; Trivedi P; Kumar D
    Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
    Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
    Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential drug repurposing of ruxolitinib to inhibit the JAK/STAT pathway for the treatment of patients with epithelial ovarian cancer.
    Yunianto I; Currie M; Chitcholtan K; Sykes P
    J Obstet Gynaecol Res; 2023 Nov; 49(11):2563-2574. PubMed ID: 37565583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.
    Zalpoor H; Nabi-Afjadi M; Forghaniesfidvajani R; Tavakol C; Farahighasreaboonasr F; Pakizeh F; Dana VG; Seif F
    Cell Mol Biol Lett; 2022 Jul; 27(1):60. PubMed ID: 35883021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
    Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
    Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia.
    Moser B; Edtmayer S; Witalisz-Siepracka A; Stoiber D
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.
    Furqan M; Mukhi N; Lee B; Liu D
    Biomark Res; 2013 Jan; 1(1):5. PubMed ID: 24252238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
    Klein K; Stoiber D; Sexl V; Witalisz-Siepracka A
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the JAK/STAT signal pathway in rheumatoid arthritis.
    Malemud CJ
    Ther Adv Musculoskelet Dis; 2018 Jun; 10(5-6):117-127. PubMed ID: 29942363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase JAK1 maintains the ovarian reserve of primordial follicles in the mouse ovary.
    Sutherland JM; Frost ER; Ford EA; Peters AE; Reed NL; Seldon AN; Mihalas BP; Russel DL; Dunning KR; McLaughlin EA
    Mol Hum Reprod; 2018 Nov; 24(11):533-542. PubMed ID: 30247637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
    Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
    Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours.
    Thomas SJ; Snowden JA; Zeidler MP; Danson SJ
    Br J Cancer; 2015 Jul; 113(3):365-71. PubMed ID: 26151455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
    Tzeng HT; Chyuan IT; Lai JH
    Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer.
    Jia J; Zhou X; Chu Q
    Mol Cell Biochem; 2024 Mar; ():. PubMed ID: 38519710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.